A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 368-372

  Puls, Larry E ^a   Phillips, Bunny ^a   Schammel, Chris ^b   Hunter, James E ^a   Griffin, David ^a  

^a Cancer Centers of the Carolinas   (United States)

^b FURMAN UNIVERSITY   (United States)

Author keywords

Cervical carcinoma; Chemotherapy forrecurrent cervical cancer; Metastatic disease; Recurrent disease; Weekly topotecan

Indexed keywords

CISPLATIN; FLUOROURACIL; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TOPOISOMERASE I INHIBITORS; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 77956924046     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9219-7     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. doi:10.3322/ canjclin.55.2.74.
2. Jemal A, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
3. Rose PG, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-53. doi:10.1056/NEJM199904153401502. (Pubitemid 29177873)
4. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 1981;48:899-903. doi:10.1002/1097-0142(19810 815)48:4\899::AID-CNCR2820480406[3.0.CO;2-6. (Pubitemid 11049085)
5. Long HJ 3rd, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626-33. doi:10.1200/JCO.2005.10.021. (Pubitemid 46224065)
6. Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr, Hatch KD. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1989;32:198-202. doi:10.1016/S0090-8258(89)80033-2. (Pubitemid 19041962)
7. Bonomi P, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3:1079-85.
8. Lele SB, Piver MS. Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma. Gynecol Oncol. 1989;33:6-8. doi:10.1016/0090-8258(89)90594-5. (Pubitemid 19106615)
9. Reichman B, et al. Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy. Gynecol Oncol. 1991;43:159-63. doi:10.1016/0090- 8258(91)90064-C.
10. Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007;25:2966-74. doi:10.1200/ JCO.2006.09.3781.
11. Fiorica J, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002;85:89-94. doi:10.1006/ gyno.2001.6557.
12. Abushahin F, et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2008;108:53-7. doi:10.1016/j.ygyno.2007.08.062. (Pubitemid 350299419)
13. Vandenput I, et al. Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:83-7. doi:10.1111/j.1525-1438.2007.00789.x. (Pubitemid 46213974)
14. Spannuth WA, et al. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol. 2007;104:591-5. doi:10.1016/j.ygyno.2006. 09.008.
15. Rose PG, Smrekar M, Haba P, Visser C, Beeler JF. A phase I/II trial of weekly topotecan and carboplatin in potentially platinumsensitive relapsed ovarian and peritoneal carcinoma. Gynecol Oncol. 2005;99:714-9. doi:10.1016/j.ygyno.2005.07.020. (Pubitemid 41686557)
16. O'Malley DM, et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2005;98:242-8. doi:10.1016/j.ygyno.2005.04.032. (Pubitemid 41019112)
17. Homesley HD, et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol. 2001;83:394-9. doi:10.1006/gyno.2001.6435. (Pubitemid 33033085)
18. Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16. doi:10.1093/jnci/92.3.205.
19. Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000;77:446-9. doi:10.1006/gyno.2000.5807. (Pubitemid 30368565)
20. Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 2001;81:213-5. doi:10.1006/gyno.2000.6024. (Pubitemid 32424163)
21. Garcia AA, et al. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a Gynecologic Oncology Group Study. Gynecol Oncol. 2007;104:572-9. doi:10.1016/j.ygyno.2006.09.002. (Pubitemid 46240236)
22. Goncalves A, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2008;108:42-6. doi:10.1016/j.ygyno. 2007.07.057.
23. Pearl ML, Johnston CM, McMeekin DS. A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix. Gynecol Obstet Invest. 2007;64:193-8.
24. Rose PG, Blessing JA, Lele S, Abulafia O. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;102:210-3. doi:10.1016/j.ygyno.2005.11.048. (Pubitemid 44041633)